Skip to main content
Premium Trial:

Request an Annual Quote

William Knight, Peter Wilver, Theo Melas-Kyriazi, Aaron Ciechanover, Avram Hershko, Irwin Rose, Ingelise Saunders, Ejvind Mortz


William Knight has been appointed as the new chief financial officer of Bruker BioSciences, effective Oct. 25. Before joining Bruker, Knight was chief financial officer of Anika Therapeutics, a medical device company based in Woburn, Mass. Prior to that, Knight was chief financial officer for Zykos, NMT Medical, and Zoll Medical.

From 1982 to 1996, Knight was one of the founders and senior executives of Analytical Technology, a scientific instrumentation company that posted $125 million in revenues in 1995. Knight is a certified public accountant and began his career as an auditor with the accounting and tax firm Grant Thornton.

Peter Wilver has replaced Theo Melas-Kyriazi as chief financial officer of Thermo Electron, the company said in an SEC filing this week. Melas-Kyriazi had announced his resignation in June, effective Oct. 1. Wilver takes the CFO post after serving as Thermo’s vice president of financial operations since October 2000. Previously, he was vice president and chief financial officer of Honeywell International’s electronic materials division and served as finance director of its aerospace aftermarket services business.

Aaron Ciechanover, Avram Hershko, and Irwin Rose have won this year’s Nobel Prize in chemistry for their studies of ubiquitin-mediated protein degradation, the Royal Swedish Academy of Sciences announced last week. At the beginning of the 1980s, they discovered how cells degrade proteins in a regulated way. Ciechanover, 57, and Hershko, 67, are both professors at the Technion-Israel Institute of Technology in Haifa, Israel. Ciechanover received his medical degree from the same institution. Hershko holds a medical degree from the Hadassah Medical School of the Hebrew University in Jerusalem. Rose, 78, is a specialist at the University of California, Irvine. He holds a doctorate from the University of Chicago. The three laureates will equally share the SEK 10 million ($1.4 million) prize.

ACE BioSciences announced last week that it has appointed Ingelise Saunders as CEO. Saunders replaces Ejvind Mortz, who co-founded the ACE in 2001.

Before joining ACE, Saunders was CEO of Celltech Pharmaceuticals for three years until the company was acquired by UCB in May.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.